| CASE REPORT |
|
| Year : 2013 | Volume
: 17
| Issue : 2 | Page : 326-328 |
|
|
Carbimazole-induced cholestatic hepatitis in Graves' disease
Sunil K Kota1, Lalit K Meher2, Siva K Kota3, Sruti Jammula4, Kirtikumar D Modi1
1 Department of Endocrinology, Medwin Hospital, Hyderabad, Andhra Pradesh, India
2 Department of Medicine, MKCG Medical College, Berhampur, Orissa, India
3 Department of Anesthesia, Central Security Hospital, Riyadh, Saudi Arabia
4 Department of Pharmaceutics, Roland Institute of Pharmaceutical Sciences, Berhampur, Orissa, India
Correspondence Address:
Sunil K Kota
Department of Endocrinology, Medwin Hospital, Chiragh Ali Lane, Nampally, Hyderabad - 500 001
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2230-8210.109660
|
|
|
Antithyroid medications are one of the treatment options for Graves' disease. Carbimazole is widely used as the drug of choice, except in pregnancy, where propythiouracil is preferred by many. It is generally well-tolerated. Its side-effects include allergy, upper gastrointestinal upset, a rare occurrence of granulocytosis, and others. Hepatitis is another rare, but serious side-effect. We report a healthy 30-year-old male patient with Graves' disease, who developed cholestatic jaundice after Carbimazole therapy for four months. He made a full recovery after the drug was discontinued. An idiosyncratic mechanism seemed likely. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
